5.1 Seeking Unapproved Drugs/Devices: The Boao Lecheng Process

The "Special Zone" Solution for Exhausted Options

The Hainan Boao Lecheng International Medical Tourism Pilot Zone is China's only legal gateway for patients to access pharmaceuticals and medical devices not yet approved for general use in mainland China. Established as a national policy experiment, it functions under "Four Specials" permissions (特许医疗). This is not a loophole; it is a highly regulated, government-sanctioned pathway for patients who have exhausted standard therapies.

The Core Mechanism: "Real-World Data" (RWD) as a Regulatory Bridge

1. Application: A hospital within Lecheng applies to using a specific unapproved product for a specific patient.

2. Expert Review: A national panel of medical experts reviews the patient's case to confirm medical necessity and appropriateness.

3. Approval & Import: Upon approval, the product is imported under special customs clearance for that single patient.

4. Data Collection: The patient's outcome data is collected as part of a national "Real-World Data" study, which can later support the product's full regulatory approval in China.

The Patient Journey to Lecheng:

1. Eligibility Gate: You must have a confirmed diagnosis and have exhausted standard treatments available in your home country and China. "Doctor-shopping" for a first-line treatment is not accepted.

2. The Mandatory Triage: You cannot travel to Lecheng without pre-approval. The process starts remotely:

   • Submit complete medical records to the International Patient Department of a Lecheng hospital (e.g., Boao Super Hospital, Ruijin Hainan).

   • The hospital's expert team conducts a remote review. If they believe you are a candidate for a specific therapy available in the zone, they will initiate the application process.

   • Only upon receiving a formal "Treatment Acceptance Letter" should you make travel arrangements.

3. Cost & Insurance: Therapies are typically self-paid and extremely expensive (often hundreds of thousands of USD). Some international insurers are beginning to cover treatments in Lecheng on a case-by-case, pre-authorization basis. Domestic Chinese "Special Drug Insurance" (特药险) may cover a portion.

Critical Considerations:

• It's About Specific Drugs/Devices, Not General Care: Lecheng is for accessing a specific product (e.g., a new-generation CAR-T, a targeted cancer drug, a novel spinal implant). It is not a general "best hospital" destination.

• Managed Expectations: Success is not guaranteed. Outcomes with experimental therapies vary. The process is bureaucratic and slow (often 2-4 months from application to treatment).

• Follow-up is Tied to China: Post-treatment monitoring and data collection are required, which may necessitate multiple return trips to Hainan.

---